ST. LOUIS – C2N Diagnostics has introduced two new plasma-based blood tests designed to support clinical researchers studying Alzheimer’s disease and related dementias. The assays, available for Research Use Only, aim to provide more precise insights into disease progression, neurofibrillary tangles, and treatment response.
The first test, C2N eMTBR-tau243, targets a specific fragment of tau protein associated with insoluble tau aggregates found in neurofibrillary tangles, a key pathological feature of Alzheimer’s. The new plasma version builds on an earlier cerebrospinal fluid assay launched by the company and is based on technology licensed from the Bateman Lab at Washington University School of Medicine. Funded by the GHR Foundation, the test was optimized using rigorous analytical processes to improve diagnostic accuracy in clinical trial settings.
The second assay, C2N %p-tau MAA, uses high-resolution mass spectrometry to measure multiple forms of phosphorylated and nonphosphorylated tau proteins from a single blood sample. By calculating ratios such as %p-tau181, %p-tau205, and %p-tau217, this multi-analyte approach helps mitigate the impact of confounding variables like age and kidney disease. C2N says the test could improve the ability to stage disease, monitor therapy, and stratify patients for clinical trials.
“Our introduction of the C2N eMTBR-tau243 blood test and the C2N %p-tau MAA demonstrates C2N’s commitment to clinically-relevant innovations and advancing brain health diagnostics,” said Dr. Joel Braunstein, CEO and President of C2N Diagnostics. “Patients and families worried about Alzheimer’s disease are pressing on the entire healthcare sector for a clearer picture of Alzheimer’s disease pathology. We are responding, first for researchers and then for the broader global healthcare provider community.”
C2N expects the assays to be widely used in biopharma-sponsored Alzheimer’s trials and believes they will support a more precise approach to developing and evaluating new treatments. The tests are intended to help detect both early- and late-stage tau pathology, improving researchers’ ability to track disease progression and tailor therapies.
C2N’s existing clinical test portfolio includes PrecivityAD®, PrecivityAD2™, and Precivity-ApoE™, which are already used by healthcare providers to detect amyloid plaques in the brain and guide diagnosis and treatment decisions for Alzheimer’s disease.
